[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA28703B1 - Dérivés d'hétéroaryle et phénylsulfamoyle substitués - Google Patents

Dérivés d'hétéroaryle et phénylsulfamoyle substitués

Info

Publication number
MA28703B1
MA28703B1 MA29590A MA29590A MA28703B1 MA 28703 B1 MA28703 B1 MA 28703B1 MA 29590 A MA29590 A MA 29590A MA 29590 A MA29590 A MA 29590A MA 28703 B1 MA28703 B1 MA 28703B1
Authority
MA
Morocco
Prior art keywords
heteroaryl
derivatives
phenylsulfamoyl
substituted
substituted phenylsulfamoyl
Prior art date
Application number
MA29590A
Other languages
English (en)
Inventor
Ernest Seiichi Hamanaka
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA28703B1 publication Critical patent/MA28703B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/27—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
MA29590A 2004-06-29 2006-12-29 Dérivés d'hétéroaryle et phénylsulfamoyle substitués MA28703B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58372104P 2004-06-29 2004-06-29

Publications (1)

Publication Number Publication Date
MA28703B1 true MA28703B1 (fr) 2007-06-01

Family

ID=35241182

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29590A MA28703B1 (fr) 2004-06-29 2006-12-29 Dérivés d'hétéroaryle et phénylsulfamoyle substitués

Country Status (27)

Country Link
US (3) US20050288340A1 (fr)
EP (1) EP1765796A1 (fr)
JP (1) JP2008505170A (fr)
KR (1) KR20070030287A (fr)
CN (1) CN101287718A (fr)
AP (1) AP2007003889A0 (fr)
AR (1) AR054665A1 (fr)
AU (1) AU2005258906A1 (fr)
BR (1) BRPI0512624A (fr)
CA (1) CA2573193A1 (fr)
CR (1) CR8881A (fr)
EA (1) EA200602273A1 (fr)
EC (1) ECSP067125A (fr)
GT (1) GT200500173A (fr)
IL (1) IL180426A0 (fr)
MA (1) MA28703B1 (fr)
MX (1) MX2007000289A (fr)
NL (1) NL1029360C2 (fr)
NO (1) NO20070511L (fr)
PA (1) PA8638001A1 (fr)
PE (1) PE20060415A1 (fr)
SV (1) SV2006002158A (fr)
TN (1) TNSN06447A1 (fr)
TW (1) TW200611690A (fr)
UY (1) UY28988A1 (fr)
WO (1) WO2006003495A1 (fr)
ZA (1) ZA200610783B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
JP2009507846A (ja) * 2005-09-07 2009-02-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
JP2009084156A (ja) * 2006-01-18 2009-04-23 Nissan Chem Ind Ltd チアゾール置換アセトニトリルの製造方法
EP1991536A2 (fr) * 2006-02-15 2008-11-19 Abbott Laboratories Nouveaux inhibiteurs d'acétyl-coa carboxylase (acc) et leur utilisation dans le traitement du diabète, de l'obésité et du syndrome métabolique
CN103554095A (zh) * 2006-02-15 2014-02-05 Abbvie公司 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
AU2008214095B2 (en) 2007-02-02 2014-07-10 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9233941B2 (en) 2007-02-02 2016-01-12 Baylor College Of Medicine Methods and compositions for the treatment of body weight related disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US9085566B2 (en) 2007-02-02 2015-07-21 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and related disorders
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US8076491B2 (en) 2007-08-21 2011-12-13 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
KR101558193B1 (ko) * 2007-08-21 2015-10-12 세노믹스, 인코포레이티드 인간 ｔ2ｒ 쓴맛 수용체 및 이의 용도
US20100324075A1 (en) * 2007-12-21 2010-12-23 University Of Cincinnati Therapeutic use of carboxyl ester lipase inhibitors
WO2009112445A1 (fr) * 2008-03-10 2009-09-17 Novartis Ag Procédé d’accroissement de phosphatidyl-choline des cellules par l’inhibition de la dgat1
WO2011028309A1 (fr) 2009-09-04 2011-03-10 University Of Toledo Procédés de fabrication de bêta-lactones optiquement pures à partir d'aldéhydes et compositions obtenues par ces procédés
AU2013308963A1 (en) 2012-08-27 2015-03-19 University Of Tennessee Research Foundation LPA2 receptor-specific benzoic acid derivatives
US9682085B2 (en) 2013-02-22 2017-06-20 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
WO2014150395A1 (fr) 2013-03-15 2014-09-25 Shifa Biomedical Corporation Composés anti-pcsk9 et méthodes de traitement et/ou de prévention de maladies cardio-vasculaires
CN105228616B (zh) * 2013-03-15 2019-05-03 实发生物医学公司 抗前蛋白转化酶枯草杆菌蛋白酶Kexin 9型（抗PCSK9）化合物及其用于治疗和/或预防心血管疾病的方法
WO2015145371A1 (fr) * 2014-03-27 2015-10-01 Piramal Enterprises Limited Modulateurs de ror-gamma et leurs utilisations
JP6578349B2 (ja) 2014-08-11 2019-09-18 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
EP3240778A4 (fr) 2014-12-31 2018-07-11 Angion Biomedica Corp. Méthodes et agents pour traiter une maladie
KR102370515B1 (ko) 2016-06-21 2022-03-03 시파 바이오메디칼 코포레이션 항-프로단백질 전환효소 서브틸리신 켁신 유형 9(항-pcsk9) 화합물 및 심혈관 질환의 치료 및/또는 예방에 이를 사용하는 방법
CN107898821A (zh) * 2017-11-10 2018-04-13 四川维尔康动物药业有限公司 一种用于菌毒并治的组合药物及其制备方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
US3658990A (en) * 1969-06-10 1972-04-25 Ciba Geigy Corp Diuretic compositions
US3806542A (en) * 1969-06-10 1974-04-23 Ciba Geigy Corp 5-arylsulfamyl-anthranilic acids
US3843662A (en) * 1971-12-09 1974-10-22 Pfizer 2-halo-5-(substituted piperidino sulfonyl)benzoic acids
DE2125229C3 (de) * 1971-05-21 1979-06-13 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Chinazolinen
US3812104A (en) * 1971-06-25 1974-05-21 Ciba Geigy Corp 5-arylsulfamyl-anthranilic acids
US3992441A (en) * 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
US4377521A (en) * 1972-12-26 1983-03-22 Pfizer Inc. Sulfamylbenzoic acids
US4062950A (en) * 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
US3879402A (en) * 1973-09-26 1975-04-22 Pfizer Process for preparing 2-chloro-5-sulfamoylbenzoic acids
US3894033A (en) * 1974-05-16 1975-07-08 Pfizer 5-Aryltetrazoles
US3929803A (en) * 1974-05-28 1975-12-30 Pfizer Aryl carboxylic acids
JPS5612114B2 (fr) * 1974-06-07 1981-03-18
DE2719912C3 (de) * 1977-05-04 1979-12-06 Bayer Ag, 5090 Leverkusen Verfahren zur Isolierung von 0- |4,6-Dideoxy-4- [JJl S-O,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2cyclohexen-1-yl] -amino] - a -D-glucopyranosyl} -(I Pfeil nach rechts 4)-0- a D-glucopyranosyl-(l Pfeil nach rechts 4)-D-glucopyranose aus Kulturbrühen
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
JPS5953920B2 (ja) * 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
CA1121290A (fr) * 1978-02-14 1982-04-06 Yasuji Suhara Derives amines d'un sucre
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
ES505959A0 (es) * 1980-10-09 1982-09-01 Hoechst Ag Procedimiento para la preparacion de un inactivador de alfa-amilasa
DE3166093D1 (en) * 1981-01-05 1984-10-18 Takeda Chemical Industries Ltd N-substituted pseudo-aminosugars, their production and use
DE3275332D1 (en) * 1981-09-02 1987-03-05 Toshiba Kk Magnetic focusing type cathode ray tube
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
FI844289A7 (fi) * 1984-01-21 1985-07-22 Hoechst Ag Uusia polypeptidejä, joilla on -amylaasi-estävä vaikutus, niiden käyttö ja farmaseuttiset valmistee
US4634765A (en) * 1984-12-18 1987-01-06 Merrell Dow Pharmaceuticals Inc. Homodisaccharide hypoglycemic agents
US5061798A (en) * 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8608335D0 (en) * 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5041432A (en) * 1987-01-30 1991-08-20 E. I. Du Pont De Nemours And Company Steroid derivatives useful as hypocholesterolemics
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5192772A (en) * 1987-12-09 1993-03-09 Nippon Shinyaku Co. Ltd. Therapeutic agents
US4804770A (en) * 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
EP0344383A1 (fr) * 1988-06-02 1989-12-06 Merrell Dow Pharmaceuticals Inc. Inhibiteurs d'alpha-glucosidase
DE3836675A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Glykosidase-inhibitor salbostatin, verfahren zu seiner herstellung und seine verwendung
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5504078A (en) * 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
EP0618803A4 (fr) * 1991-12-19 1995-03-22 Southwest Found Biomed Res Polypeptide inhibant la proteine de transfert aux esters de cholesteryl, anticorps contre le polypeptide synthetique et traitements prophylactiques et therapeutiques anti-atherosclerose.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
DK0580550T3 (da) * 1992-07-21 1998-02-02 Ciba Geigy Ag Oxamidsyrederivater som hypercholesterolæmiske midler
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
JPH06332264A (ja) * 1993-05-24 1994-12-02 Hodogaya Chem Co Ltd 静電荷像現像用トナー
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
ATE198889T1 (de) * 1994-10-27 2001-02-15 Janssen Pharmaceutica Nv Apolipoprotein-b syntheseinhibitoren
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors
FI974436A7 (fi) * 1995-06-06 1998-01-27 Pfizer Substituoituja N-(indoli-2-karbonyyli)-glysiiniamideja ja -johdannaisi a glykogeenifosforylaasi-inhibiittoreina
ATE233734T1 (de) * 1995-06-07 2003-03-15 Pfizer Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6 yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
JP3656680B2 (ja) * 1995-09-21 2005-06-08 株式会社リコー 可逆性感熱発色組成物、およびそれを用いた可逆性記録媒体
US6040413A (en) * 1996-07-10 2000-03-21 Basf Corporation Composition of polytetramethylene ether glycols and polyoxy alkylene polyether polyols having a low degree of unsaturation
TR199901180T2 (xx) * 1996-11-27 1999-08-23 Pfizer Inc. Apo B-Salg�lama/MTP inhibit�r amidler.
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
PL338016A1 (en) * 1997-07-11 2000-09-25 Smithkline Beecham Plc Novel chemical compounds
ATE282591T1 (de) * 1997-12-23 2004-12-15 Warner Lambert Co Thioharnstoffverbindungen, zusammensetzungen sowie verfahren zur behandlung oder verhütung von entzündlichen erkrankungen und atherosklerose
US6583157B2 (en) * 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
DE69939864D1 (de) * 1998-01-29 2008-12-18 Amgen Inc Ppar-gamma modulatoren
ES2164040T3 (es) * 1998-04-14 2008-02-01 The General Hospital Corporation Uso de d-serina o de d-alanina para el tratamiento de la esquizofrenia.
IL141769A0 (en) * 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
AU6118001A (en) * 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
EA005976B1 (ru) * 2000-06-28 2005-08-25 Туларик Инк. Хинолинил и бензотиазолил ppar-гамма модуляторы
UA82048C2 (uk) * 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
IL156462A0 (en) * 2001-03-30 2004-01-04 Pfizer Prod Inc Pyridazinone aldose reductase inhibitors
SK14912003A3 (sk) * 2001-06-07 2004-09-08 Eli Lilly And Company Modulátory receptorov aktivovaných peroxizomálnymi proliferátormi (PPAR)
TW550839B (en) * 2001-07-25 2003-09-01 Shinetsu Handotai Kk Light emitting element and method for manufacturing thereof
US7371777B2 (en) * 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
ATE375350T1 (de) * 2002-02-21 2007-10-15 Lilly Co Eli Modulatoren von peroxisome proliferator- aktivierten rezeptoren
US20050171161A1 (en) * 2002-03-06 2005-08-04 Fong Tung M. Method of treatment or prevention of obesity
KR100741231B1 (ko) * 2002-07-29 2007-07-19 에프. 호프만-라 로슈 아게 신규 벤조다이옥솔
ES2294330T3 (es) * 2002-08-02 2008-04-01 MERCK & CO., INC. Derivados de furo(2,3-b)piridina sustituidos.
WO2004019932A1 (fr) * 2002-08-30 2004-03-11 Pharmacia & Upjohn Company Methode de prevention ou de traitement d'atherosclerose ou de restenose
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20050022815A1 (en) * 2003-06-25 2005-02-03 Sunrise Medical Hhg Inc. Apparatus and method for monitoring supplemental oxygen usage
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
CN1946666A (zh) * 2004-02-27 2007-04-11 埃姆艮股份有限公司 用于治疗代谢性疾病的化合物、药物组合物和方法
JP2007527918A (ja) * 2004-03-08 2007-10-04 アムジェン インコーポレイテッド Ｐｐａｒガンマ活性の治療的調節
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US6967808B1 (en) * 2004-05-13 2005-11-22 Hitachi Global Storage Technologies Netherlands B.V. Data recording system with servo pattern having pseudo-random binary sequences
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds

Also Published As

Publication number Publication date
EP1765796A1 (fr) 2007-03-28
CN101287718A (zh) 2008-10-15
SV2006002158A (es) 2006-05-09
MX2007000289A (es) 2007-04-10
NL1029360A1 (nl) 2005-12-30
PA8638001A1 (es) 2006-06-02
US20050288340A1 (en) 2005-12-29
PE20060415A1 (es) 2006-06-02
WO2006003495A1 (fr) 2006-01-12
TNSN06447A1 (fr) 2008-02-22
ZA200610783B (en) 2008-06-25
CA2573193A1 (fr) 2006-01-12
AU2005258906A1 (en) 2006-01-12
GT200500173A (es) 2006-03-02
US20060229363A1 (en) 2006-10-12
AR054665A1 (es) 2007-07-11
UY28988A1 (es) 2006-01-31
IL180426A0 (en) 2007-06-03
EA200602273A1 (ru) 2007-06-29
TW200611690A (en) 2006-04-16
CR8881A (es) 2007-03-19
ECSP067125A (es) 2007-03-29
NO20070511L (no) 2007-03-22
KR20070030287A (ko) 2007-03-15
AP2007003889A0 (en) 2007-02-28
US20080090829A1 (en) 2008-04-17
BRPI0512624A (pt) 2008-03-25
JP2008505170A (ja) 2008-02-21
NL1029360C2 (nl) 2006-07-12

Similar Documents

Publication Publication Date Title
MA28703B1 (fr) Dérivés d'hétéroaryle et phénylsulfamoyle substitués
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
EP2096923A4 (fr) Dérivés d'hétéroaryl-amides
CY2017048I2 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
NO20043996L (no) Fremgangsmate for frembringelse av API'er
EP1737861A4 (fr) Inhibiteurs de l'activite d'akt
EP1771786A4 (fr) Multitraitement d'echantillons
DE60325879D1 (de) Selbstverschliessende kanüle
NO20041272L (no) Tetracycline derivatives and methods of use thereof
PL376575A1 (pl) Podstawione związki heterocykliczne oraz sposoby wykorzystania
CY2015007I1 (el) Ενωσεις, συνθεσεις και χρησεις παραγωγων βενζοθειαζολης
EP1752150A4 (fr) Préparation d'irinotécan
DE60334292D1 (de) Ylenverbundemulsionszusammensetzung und verwendung davon
EP1924684A4 (fr) Structure de l'état de transition de 5'-méthylthioadénosine/s-adénosylhomocystéine nucléosidases
NO20044916L (no) Preparater av sulfinylacetamid
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
NL1028519A1 (nl) Gesubstitueerde heteroaryl- en fenylsulfamoylverbindingen.
DE602004004794D1 (de) Nicotinamid-derivate verwendbar als pde4 inhibitoren
MA28812B1 (fr) Combinaisons d'epothilone
PL1786759T3 (pl) Nowe pochodne 3,5-seko-4-norcholestanowe i ich zastosowanie
PT1392670E (pt) Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina
EP1764362A4 (fr) Dérivés de biaryles
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
ITMI20041199A1 (it) Composizioni di coloranti e loro utilizzo
EP1534158A4 (fr) Compositions et methodes de cryochirurgie